{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:03:10Z","timestamp":1761933790307,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","interventional.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.iccl.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T07:09:53Z","timestamp":1622099393000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation in ST-Elevation Myocardial Infarction"],"prefix":"10.1016","volume":"10","author":[{"given":"Chirag","family":"Bavishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Dawn","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.iccl.2021.03.003_bib1","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/hc3801.095588","article-title":"Circulating monocyte-platelet aggregates are a more sensitive marker of in\u00a0vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction","volume":"104","author":"Michelson","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.iccl.2021.03.003_bib2","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2017.08.018","article-title":"Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI","volume":"70","author":"Giustino","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2021.03.003_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/eurheartj\/ehn008","article-title":"Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial","volume":"29","author":"Montalescot","year":"2008","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.iccl.2021.03.003_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention","volume":"110","author":"Brener","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.iccl.2021.03.003_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ehjcvp\/pvz015","volume":"6","author":"Sharma","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"10.1016\/j.iccl.2021.03.003_bib6","doi-asserted-by":"crossref","first-page":"e002044","DOI":"10.1161\/CIRCINTERVENTIONS.114.002044","article-title":"Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA\/OASIS-8 Trial","volume":"8","author":"Ducrocq","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2021.03.003_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.iccl.2021.03.003_bib8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9792","key":"10.1016\/j.iccl.2021.03.003_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.iccl.2021.03.003_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2012.11.018","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2021.03.003_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.iccl.2021.03.003_bib12","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iccl.2021.03.003_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"issue":"9957","key":"10.1016\/j.iccl.2021.03.003_bib14","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.iccl.2021.03.003_bib15","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.iccl.2021.03.003_bib16","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iccl.2021.03.003_bib17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.iccl.2021.03.003_bib18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.iccl.2021.03.003_bib19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iccl.2021.03.003_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamacardio.2016.5669","article-title":"Effect of short procedural duration with bivalirudin on increased risk of acute stent thrombosis in patients with STEMI: a secondary analysis of the HORIZONS-AMI randomized clinical trial","volume":"2","author":"Tamez","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.iccl.2021.03.003_bib21","doi-asserted-by":"crossref","first-page":"i4935","DOI":"10.1136\/bmj.i4935","article-title":"Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial","volume":"354","author":"Leonardi","year":"2016","journal-title":"BMJ"},{"year":"2017","series-title":"A\u00a0randomized trial of Bivalirudin versus Heparin Monotherapy. The STEMI cohort","author":"James","key":"10.1016\/j.iccl.2021.03.003_bib22"},{"issue":"6","key":"10.1016\/j.iccl.2021.03.003_bib23","first-page":"502","article-title":"Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a subgroup analysis of the VALIDATE-SWEDEHEART trial","volume":"8","author":"Venetsanos","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"3","key":"10.1016\/j.iccl.2021.03.003_bib24","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.4244\/EIJ-D-18-00247","article-title":"Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial","volume":"15","author":"Gargiulo","year":"2019","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.iccl.2021.03.003_bib25","doi-asserted-by":"crossref","first-page":"e005628","DOI":"10.1161\/CIRCINTERVENTIONS.117.005628","article-title":"Anticoagulant use among patients with end-stage renal disease undergoing percutaneous coronary intervention: an analysis from the National Cardiovascular Data Registry","volume":"11","author":"Washam","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.iccl.2021.03.003_bib26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jcin.2011.06.012","volume":"4","author":"Saltzman","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2021.03.003_bib27","unstructured":"Stone GW, Erlinge D, Valgimigli M, et\u00a0al. Individual patient data pooled analysis of randomized trials of bivalirudin versus heparin in acute myocardial infarction. Presented on October 14, 2020 at TCT 2020. Virtual Meeting."},{"issue":"1","key":"10.1016\/j.iccl.2021.03.003_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5482\/HAMO-13-09-0048","article-title":"Anticoagulation during and after acute coronary syndrome","volume":"34","author":"Ahrens","year":"2014","journal-title":"Hamostaseologie"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745821000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745821000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:59:09Z","timestamp":1761933549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745821000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2211745821000195"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2021.03.003","relation":{},"ISSN":["2211-7458"],"issn-type":[{"type":"print","value":"2211-7458"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in ST-Elevation Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}